• +1-646-491-9876
    • +91-20-67278686

    Search

    Serine Protein Kinase ATM-Pipeline Review H1 2017

    Serine Protein Kinase ATM-Pipeline Review H1 2017

    • Report Code ID: RW0001834422
    • Category Pharmaceuticals
    • No. of Pages 28
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) - Pipeline Review, H1 2017

    Summary

    Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) pipeline Target constitutes close to 6 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes. The latest report Serine Protein Kinase ATM - Pipeline Review, H1 2017, outlays comprehensive information on the Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA) , route of administration (RoA) and molecule type.

    Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) - Serine Protein Kinase ATM is a serine/threonine protein kinase. It activates checkpoint signaling upon double strand breaks (DSBs) , apoptosis and genotoxic stresses such as ionizing ultraviolet A light (UVA) , thereby acting as a DNA damage sensor. It plays a role in replication-dependent histone mRNA degradation. It binds DNA ends. The molecules developed by companies in Phase I, Preclinical and Discovery stages are 1, 3 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Ophthalmology and Toxicology which include indications Adenocarcinoma, Breast Cancer, Colon Cancer, Colorectal Cancer, Gastric Cancer, Head And Neck Cancer, Herpetic Keratitis, Metastatic Cancer, Multiple Myeloma (Kahler Disease) , Radiation Toxicity (Radiation Sickness and Acute Radiation Syndrome) .

    Furthermore, this report also reviewsalso reviews key players involved in Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The report provides a snapshot of the global therapeutic landscape for Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1)
    - The report reviews Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
    - The report assesses Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) - Overview
    Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) - Therapeutics Development
    Products under Development by Stage of Development
    Products under Development by Therapy Area
    Products under Development by Indication
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) - Therapeutics Assessment
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) - Companies Involved in Therapeutics Development
    AstraZeneca Plc
    InteRNA Technologies BV
    Shuttle Pharmaceuticals LLC
    Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) - Drug Profiles
    Antisense RNAi Oligonucleotide to Inhibit Mutated Ataxia Telangiectasia Gene for Head and Neck Cancer - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AZD-0156 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    KU-55933 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    KU-59403 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SP-1161 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SP-3001 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) - Product Development Milestones
    Featured News & Press Releases
    Apr 18, 2016: AstraZeneca Presents Data On Next-generation Investigational ATM Inhibitor at the AACR 2016 Annual Meeting
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Indication, H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Number of Products under Investigation by Universities/Institutes, H1 2017
    Products under Investigation by Universities/Institutes, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Pipeline by AstraZeneca Plc, H1 2017
    Pipeline by InteRNA Technologies BV, H1 2017
    Pipeline by Shuttle Pharmaceuticals LLC, H1 2017

    List of Figures

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Top 10 Indications, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    AstraZeneca Plc
    InteRNA Technologies BV
    Shuttle Pharmaceuticals LLC

    Request for Sample

    Report Url https://www.reportsweb.com//serine-protein-kinase-atm-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//serine-protein-kinase-atm-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//serine-protein-kinase-atm-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments